We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Coherus BioSciences Inc | NASDAQ:CHRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -3.97% | 1.45 | 1.37 | 1.72 | 1.5077 | 1.44 | 1.50 | 1,405,693 | 05:00:01 |
From Jan 2024 to Jan 2025
By David Sachs
Sandoz will buy vision-impairment drug Cimerli from Coherus BioSciences for $170 million.
The Swiss pharmaceutical company said Monday that the purchase of the U.S. company's medication includes a biologics license, product inventory, and ophthalmology sales, as well as access to proprietary commercial software.
The medication, which treats serious eye conditions including macular degeneration, is interchangeable with Lucentis, a drug developed by Genentech. Sandoz expects to close the deal in the second half of this year.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
January 22, 2024 01:44 ET (06:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Coherus BioSciences Chart |
1 Month Coherus BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
